We've found 11 total results for "Hypersensitivity".
The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus prednisone in participants with deleterious germline or somatic Homologous Recombination Repair (HRR) gene-mutated Metastatic Cas...
Age: 18 years - 66+
Gender: Male
The primary objective of this study is to determine whether allowing ingestion of sub-threshold amounts of peanut in those with a high threshold (tolerate at least 143 mg peanut protein on supervised double-blind, placebo-controlled oral food challenge [DBPCFC]) will...
Age: 4 - 14 years
Gender: All
This study is a multi-center, randomized, double-blind, placebo-controlled study in participants 2 to less than 56 years of age who are allergic to peanut and at least two other foods (including milk, egg, wheat, cashew, hazelnut, or walnut). While each participant ...
Age: 1 year - 55 years
Gender: All
Open-label, follow-up study for subjects who completed the EPITOPE study.
Age: 2 - 4 years
Gender: All
The purpose of this study is to evaluate the safety and tolerability of ASP0892 after intradermal (ID) injection in adolescent participants with peanut allergy.
Age: 12 - 17 years
Gender: All
The purpose of this study is to evaluate the safety and tolerability of ASP0892 after intradermal (ID) injection in adolescent participants with peanut allergy.
Age: 12 - 17 years
Gender: All
The purpose of this study is to determine the efficacy and safety of AR101 in peanut‑allergic children aged 1 to < 4 years.
Age: 1 year - 3 years
Gender: All
The purpose of this study is to assess AR101's safety and tolerability over an extended dosing period.
Age: 1 year - 55 years
Gender: All
The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT).
Age: 1 year - 3 years
Gender: All
The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101 through characterized oral desensitization immunotherapy (CODIT) in peanut-allergic children and adults who have completed the ARC003 study.
Age: 4 - 55 years
Gender: All
The aim of this study is to confirm safety and tolerability of incremental doses of HAL-MPE1 subcutaneous immunotherapy (SCIT) in peanut allergic adults, and subsequently assess the safety and tolerability in adolescents and children with peanut allergy.
Age: 5 - 50 years
Gender: All